Abstract

PurposeTo evaluate the diagnostic values of systemic immune-inflammation index (SII) and neutrophil–lymphocyte ratio (NLR) in patients with localized prostate cancer (PCa).MethodsBetween January 2014 and December 2019, 117 patients with benign prostate hyperplasia (BPH) and 278 patients with localized PCa who underwent radical prostatectomy (RP) were included in this study. The inflammatory markers including SII, NLR, platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), lymphocyte ratio (LR), neutrophil ratio (NR), mean platelet volume (MPV), and red cell distribution (RDW) of these two groups were examined and analyzed. ROC curve analysis was performed to assess the discriminative ability of inflammatory markers and their combination with tPSA for PCa. The binary logistic regression model was used to evaluate the association between significant inflammatory markers and risk of PCa.ResultsThe pathological results from RP specimen comprised 72 (25.90%) patients with pT1, 168 (60.43%) patients with pT2, and 38 (13.67%) patients with pT3. According to Student’s t test, patients with PCa had higher NLR (p = 0.034), SII (p = 0.008), and NR (p = 0.004), and lower LR (p = 0.025), MPV (p = 0.003), and TPV (p = 0.022) compared with patients with BPH; the distribution of age, PLR, LMR, RDW, f/t PSA ratio, and BMI did not show any significant differences. The AUC for NLR, SII, NR, and tPSA was 0.697 (p = 0.015), 0.719 (p < 0.001), 0.647 (p = 0.009), and 0.708 (p < 0.001), with threshold values of 1.6, 471.86, 65.15%, and 12.89 ng/ml, respectively. Patients were divided into two groups according to the threshold values, respectively. By using the multivariable logistic regression models, NLR ≥ 1.6 (OR, 2.731; 95% CI, 0.937–7.961, p = 0.042), SII ≥ 471.86 (OR, 1.274; 95% CI 0.473–3.433; p = 0.033), and PSA ≥ 12.89 ng/ml (OR, 1.443; 95% CI, 0.628–3.944; p = 0.014) were independent risk factors associated with PCa. The AUC for combination of NLR, SII, and NR with tPSA was 0.705 (p < 0.001), 0.725 (p < 0.001), and 0.704 (p < 0.001), respectively.ConclusionThis study demonstrated that SII, NLR, and NR were all independent risk factors of PCa. These factors alone could provide better screen methods for PCa before biopsy. In addition, SII is a more powerful tool among these three inflammatory markers associated with PCa. Besides, combination of SII and NLR with tPSA had not much advantage compared with themselves alone.

Highlights

  • Prostate-specific antigen (PSA) is the most widely used method for predicting prostate cancer (PCa); it increases the number of tumors diagnosed at early stage [1]

  • Patients with PCa had higher neutrophil–lymphocyte ratio (NLR) (p = 0.034), systemic immune-inflammation index (SII) (p = 0.008), and neutrophil ratio (NR) (p = 0.004) and lower lymphocyte ratio (LR) (p = 0.025), mean platelet volume (MPV) (p = 0.003), and total prostate volume (TPV) (p = 0.022) compared with patients with BPH, but the distribution of age, platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), RDW, f/t PSA ratio, and body mass index (BMI) did not show any significant differences as shown in Figure 1 and Table 1

  • The ROC curve for NLR, SII, NR, LR, MPV, and TPV was plotted in the diagnosis of PCa as shown in Table 2 and Figure 2

Read more

Summary

Introduction

Prostate-specific antigen (PSA) is the most widely used method for predicting prostate cancer (PCa); it increases the number of tumors diagnosed at early stage [1]. NLR is an independent factor for overall survival after RP [5], and higher NLR was associated with tumor aggressiveness and higher Gleason Score (GS) in metastatic PCa [6]. Another novel inflammation marker, systemic immune-inflammation index (SII), has been shown to have a more powerful diagnostic and prognostic value in various kinds of tumors [7]. Both NLR and SII are all measurable and inexpensive parameters that can be calculated from complete blood counts (CBCs)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call